Valuation: Amplia Therapeutics Limited

Market Cap 7.44Cr 5.17Cr 4.53Cr 4.18Cr 3.86Cr 7.32Cr 493.34Cr 50Cr 20Cr 243.11Cr 19Cr 19Cr 836.72Cr P/E 2027 *
-6.3x
P/E 2028 * -24.2x
Enterprise Value 5.89Cr 4.1Cr 3.59Cr 3.31Cr 3.05Cr 5.79Cr 390.6Cr 40Cr 15Cr 192.48Cr 15Cr 15Cr 662.48Cr EV / Sales 2027 *
-
EV / Sales 2028 * 5.29x
Free-Float
84.81%
Yield 2027 *
-
Yield 2028 * -
1 day+7.41%
1 week-3.33%
1 month+26.09%
3 months-6.45%
6 months-17.14%
Current year-3.33%
1 week 0.14
Extreme 0.135
0.16
1 month 0.1
Extreme 0.105
0.16
Current year 0.1
Extreme 0.1
0.28
1 year 0.1
Extreme 0.1
0.4
3 years 0.05
Extreme 0.049
0.42
5 years 0.05
Extreme 0.049
0.42
10 years 0.04
Extreme 0.045
18.3
Manager TitleAgeSince
Chief Executive Officer - 05/12/2022
Director of Finance/CFO - 01/10/2021
Chief Tech/Sci/R&D Officer - 12/05/2025
Director TitleAgeSince
Director/Board Member 70 02/09/2015
Chairman - 25/05/2018
Chairman - 30/06/2026
Date Insider Type Main position Quantity % Market Cap.
08/25/08Buy

Founder

86,957 0.0224%
08/25/08Free

Director

2,40,590 0.0620%
08/25/08Fiscal year

Chairman

7,50,000 0.1933%
Change 5-day change 1-year change 3-year change Capi.($)
+7.41%-3.33%-57.35%+72.62% 4.81Cr
-4.14%-7.44%+64.26%+119.36% 5.7TCr
+1.84%+1.65%+76.90%+95.68% 5.36TCr
-2.24%+3.65%+19.60%+466.72% 2.56TCr
-1.60%-2.60%-19.69%-14.84% 2.35TCr
+2.43%+5.86%+46.56%+0.42% 1.94TCr
-3.19%-0.29%+36.24%-27.32% 1.81TCr
-6.84%+2.18%+203.03%+348.11% 1.65TCr
+8.74%+10.46%+47.66% - 1.41TCr
-1.05%+1.75%+25.08%+196.28% 1.44TCr
Average +0.14%+0.05%+44.23%+139.67% 2.42TCr
Weighted average by Cap. -1.02%+0.29%+56.78%+138.54%

Financials

2027 *2028 *
Net sales - 1Cr 69.5L 60.9L 56.14L 51.83L 98.31L 66Cr 6.71Cr 2.63Cr 33Cr 2.61Cr 2.55Cr 112.42Cr
Net income -1.16Cr -80.62L -70.64L -65.13L -60.12L -1.14Cr -77Cr -7.79Cr -3.05Cr -38Cr -3.03Cr -2.96Cr -130.4Cr -36L -25.02L -21.92L -20.21L -18.66L -35.39L -24Cr -2.42Cr -94.65L -12Cr -93.93L -91.89L -40Cr
Net Debt -1.55Cr -1.08Cr -94.39L -87.02L -80.34L -1.52Cr -102.74Cr -10Cr -4.08Cr -51Cr -4.04Cr -3.96Cr -174.25Cr -2.15Cr -1.49Cr -1.31Cr -1.21Cr -1.11Cr -2.11Cr -142.51Cr -14Cr -5.65Cr -70Cr -5.61Cr -5.49Cr -241.7Cr
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
10/26/10 A$0.1450 +7.41% 7,27,858
09/26/09 A$0.1350 -3.57% 1,70,027
08/26/08 A$0.1400 -6.67% 12,63,334
07/26/07 A$0.1500 -3.23% 5,47,528
06/26/06 A$0.1550 +3.33% 9,04,101
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1450AUD
Average target price
0.4200AUD
Spread / Average Target
+189.66%

Annual profits - Rate of surprise